Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Systagenix to co-market MiMedx EpiFix

Systagenix, a supplier of advanced wound dressings, has entered into an agreement with MiMedx Group.

Under the agreement, Systagenix will co-market MiMedx’s EpiFix and will begin its launch during March 2012.

EpiFix is an allograft which is processed through MiMedx’s proprietary Purion Process to optimize wound care and ease of use.

The Purion Process retains the amniotic growth factors inherent in and to placental tissue which promotes cellular ingrowth and enhanced healing.

As part of its distribution agreement, Systagenix will initially conduct the first phase of launch of EpiFix throughout the US, with launches in other countries to follow pending appropriate regulatory approvals.

MiMedx will also continue to sell EpiFix through its existing distributor partners.